Research output: Contribution to journal › Review › Research › peer-review
Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.
Original language | English |
---|---|
Article number | 324674 |
Journal | Journal of neurology, neurosurgery, and psychiatry |
Volume | 92 |
Issue number | 12 |
Pages (from-to) | 1325-1334 |
Number of pages | 10 |
ISSN | 0022-3050 |
DOIs | |
Publication status | Published - Dec 2021 |
ID: 62004232